ZyVersa Therapeutics
ZVSA
ZVSA was delisted on the 16th of July, 2025.
9 hedge funds and large institutions have $162K invested in ZyVersa Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
274% more capital inflows, than outflows
Capital inflows: $195K | Capital outflows: $52.1K
10.34% more ownership
Funds ownership: 3.27% → 13.61% (+10%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$167K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.9K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
+$2.85K |
| 4 |
Millennium Management
New York
|
+$2.56K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$30K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$9.7K |
| 3 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$9.05K |
| 4 |
SG
StoneX Group
New York
|
-$3.12K |
| 5 |
Barclays
London,
United Kingdom
|
-$270 |
ZVSA Hedge Fund Activity: Q3 2023 in Review
9 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q3 2023, worth a combined $162K — up 120% from $73.4K a quarter earlier.
Fund positioning in ZVSA was balanced in Q3 2023: 5 funds opened new positions, 5 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $167K. The largest seller was Virtu Financial, exiting entirely with an estimated $30K sold.
- 9 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $162K of ZyVersa Therapeutics stock for Q3 2023, up 120% quarter-over-quarter.
- 5 funds opened new ZyVersa Therapeutics positions in Q3 2023 and 5 closed out, a net change of 0 holders.
- The largest ZyVersa Therapeutics buyer in Q3 2023 was Walleye Capital, an estimated $167K added.
- The largest ZyVersa Therapeutics seller in Q3 2023 was Virtu Financial, an estimated $30K sold.
Based on aggregated 13F filings for Q3 2023.